📈 Stocks 🌍 United States

Millennium Management Doubles AbbVie Stake to 1.5 Million Shares

Millennium Management expanded its AbbVie holding to 1.5 million shares, signaling confidence in the pharmaceutical giant's dividend growth and diversified product portfolio.

📅 September 12, 2026 🕐 1 min read

1 assets impacted (Stocks). Net bias: 0 Bullish, 0 Bearish, 1 Neutral. Strongest signal: ABBV → 5/10 (60% confidence).

📊 Affected Assets (1)

ABBV

Neutral 🤖 60%

📅 Short-term 🌍 US · Explicit

Millennium Management more than doubled its stake in AbbVie, indicating confidence despite valuation concerns.

🎯 Key Takeaways

Millennium Management increased its AbbVie position by 840,718 shares, bringing the total stake to 1.5 million shares.
AbbVie’s dividend yield of 2.7% provides an estimated $10.3 million in annual income for the fund.
Despite valuation concerns and a price-to-sales ratio of 7.2, the fund maintains a long-term outlook on AbbVie's growth potential.

📝 Executive Summary

Billionaire Israel Englander’s Millennium Management has significantly increased its exposure to the pharmaceutical sector, more than doubling its stake in AbbVie to 1.5 million shares. While the firm also initiated a $3 billion position in SpaceX, the AbbVie move highlights a strategic focus on dividend-paying, diversified healthcare assets despite current valuation premiums.

❓ FAQ

Why is Millennium Management increasing its stake in AbbVie?

The fund appears to be targeting AbbVie for its diversified pharmaceutical portfolio, including key products like Skyrizi and Rinvoq, alongside a consistent history of dividend growth.

📰 Related Articles

🏷️ Tags

📰 Source

🔗 View Original Article